Recombinant antibody production employs mammalian cell lines for the generation of therapeutic antibodies. Chinese hamster ovary (CHO) cells emerged as a leading platform due to their productivity in producing complex, humanized antibodies. High-yield cultivation of CHO cells is crucial for economic viability and involves meticulous optimization of